id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
admet-2956	Chakramurty, Alendra; Rahma Dinni, Adetya ; Silvia, Ihda ; Laras Cantika, Aprilyan ; Dyah Kencono Wungu, Citrawati 	Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns: Original scientific article	2025	17	.pdf	application/pdf	8254	476	44	Heterogeneity was low for the young population for OS (I²=44 %) and zero for PFS (I²=0 %), while older patients demonstrated no heterogeneity across studies (I²=0 % for both endpoints), supporting strong and consistent age-related treatment effects. The female OS analysis revealed, nonetheless, significant heterogeneity (I²=87 %), reflecting heterogeneity of response to treatment across studies.	cache/admet-2956.pdf	txt/admet-2956.txt